Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.
10.3802/jgo.2014.25.3.214
- Author:
Weiwei SHAN
1
;
Chao WANG
;
Zhenbo ZHANG
;
Chao GU
;
Chengcheng NING
;
Xuezhen LUO
;
Qiongjie ZHOU
;
Xiaojun CHEN
Author Information
1. Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China. cxjlh@hotmail.com
- Publication Type:Original Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Endometrial hyperplasia;
Megestrol acetate;
Metformin
- MeSH:
Adult;
Antineoplastic Agents, Hormonal/*therapeutic use;
Drug Therapy, Combination;
Endometrial Hyperplasia/complications/*drug therapy/metabolism;
Female;
Humans;
Hypoglycemic Agents/*therapeutic use;
Megestrol Acetate/*therapeutic use;
Metabolic Syndrome X/complications/metabolism;
Metformin/*therapeutic use;
Pilot Projects;
Receptors, Estrogen/metabolism;
Receptors, Progesterone/metabolism;
Single-Blind Method;
Treatment Outcome
- From:Journal of Gynecologic Oncology
2014;25(3):214-220
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To compare the efficacy of metformin plus megestrol acetate (MA) with that of MA alone for treating endometrial atypical hyperplasia (EAH). METHODS: This pilot study included 16 EAH patients who met at least one metabolic syndrome (MS) criterion and received either adjunctive metformin plus MA (MET group) or MA monotherapy (MA group). Each patient in the MA group received 160 mg of MA daily, whereas patients in the MET group received the same dose of MA plus 0.5 g of metformin thrice daily. Treatment response was assessed by histological examination of dilation and curettage specimens obtained after 12 weeks of therapy. RESULTS: Each group had eight patients, and half of the patients in each group were diagnosed with MS. The complete response (CR) rate was 75% (6/8) in the MET group and 25% (2/8) in the MA group (p=0.105). Complications of MS did not affect the response rates in either group. In the MET group, 75% (3/4) of the patients had CR in the presence or absence of MS. In the MA group, 50% (2/4) of the patients with MS had CR, whereas no patient without MS had CR. No irreversible toxicities were observed. CONCLUSION: Metformin plus MA may be a potential alternative therapy for treating EAH, and the MS status of patients may have no effect on the efficacy of metformin plus MA therapy.
